Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey (CROSBI ID 202778)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Palčevski, Goran ; Skočibušić, Nataša ; Vlahović-Palčevski, Vera. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey // European journal of clinical pharmacology, 68 (2012), 7; 1073-1077. doi: 10.1007/s00228-012-1221-x

Podaci o odgovornosti

Palčevski, Goran ; Skočibušić, Nataša ; Vlahović-Palčevski, Vera.

engleski

Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey

The aim of this study was to determine the prevalence and pattern of unlicensed and off-label drugs prescribed to hospitalized children at the Department of Paediatrics, University Hospital Rijeka, Croatia. A prospective cross-sectional study was performed on 1 day each month during a 12 month period and included all hospitalized children and adolescents. A total of 1, 643 prescriptions for 198 different drugs were prescribed to 531 out of 691 (77%) hospitalized patients. Forty-six percent of the different drugs were prescribed in an unlicensed or off-label manner. Of all drug prescriptions, 25% were either unlicensed or off-label. Forty-eight percent of the patients received either an unlicensed or off-label drug. The most frequently prescribed off-label drugs were proton pump inhibitors. Unlicensed and off-label drug use is common. It is not illegal and may be clinically appropriate but is associated with a number of clinical, safety, and ethical issues. Regulatory authorities should use existing clinical evidence on the use of off-label and unlicensed drugs in decision making. Marketing authorization holders and national regulatory authorities should monitor for any safety concerns associated with unlicensed and off-label drug use and take appropriate measures as well as identify research priorities and mandate clinical studies to resolve important questions.

children . drug prescribing . unlicensed . off-label

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

68 (7)

2012.

1073-1077

objavljeno

0031-6970

10.1007/s00228-012-1221-x

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost